Skip to Content

Bretylium Pregnancy and Breastfeeding Warnings

Bretylium is also known as: Bretylol

Bretylium Pregnancy Warnings

A 39-year-old woman with long QT interval syndrome received chronic oral bretylium 800 mg three times a day during pregnancy. Pregnancy and delivery were without complications and no side effects were observed in the infant.

Bretylium has been assigned to pregnancy category C by the FDA. Animal studies have not been performed. There are no controlled data in human pregnancy. The use of bretylium during pregnancy without maternal or fetal complications has been reported. Bretylium should only be given during pregnancy when need has been clearly established.

See references

Bretylium Breastfeeding Warnings

A 39-year old woman with long QT interval syndrome received chronic oral bretylium 800 mg three times a day during pregnancy. Pregnancy and delivery were without complications and no side effects were observed in the infant. Bretylium therapy was continued following delivery and the infant was breast-feed. Appropriate infant weight gain and development were noted and periodic electrocardiograms were normal.

There are no data on the excretion of bretylium into human milk.

See references

References for pregnancy information

  1. "Product Information. Bretylol (bretylium)." DuPont Pharmaceuticals, Wilmington, DE.
  2. Gutgesell M, Overholt E, Boyle R "Oral bretylium tosylate use during pregnancy and subsequent breastfeeding: a case report." Am J Perinatol 7 (1990): 144-5
  3. Page RL "Treatment of arrhythmias during pregnancy." Am Heart J 130 (1995): 871-6

References for breastfeeding information

  1. "Product Information. Bretylol (bretylium)." DuPont Pharmaceuticals, Wilmington, DE.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide